Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
The research showed that miR-338-3p targeted the 3UTR of SLC1A5 for inhibition and degradation, while elevated glucose levels reduced SLC1A5 by enhancing miR-338-3p in RPE cells
O.YilmazB.LiH.StutzD.NoserY.et al (2019)
In placebo-controlled trials of semaglutide injection for type 2 diabetes mellitus, fatigue, dysgeusia, and dizziness were reported in greater than 0.4% of semaglutide-treated patients
*Note: Can also be administered orally, but absorption will be less
00145-1/asset/e15a739b-4aa6-4946-b7bd-35300459c77d/main.assets/gr1_lrg.jpg)
There was an overall stroke risk reduction of 17% with GLP-1 RAs across the trials ( p = 0.0002) [13], with significant reductions in the risk of both stroke overall and ischaemic stroke (both 17%) [14]
US$ 23.41
US$ 28.76
US$ 26.21
US$ 29.50
US$ 27.97
![Mechanism of action of GLP-1 [25]](https://www.researchgate.net/publication/256289222/figure/fig1/AS:614177232142337@1523442671231/Mechanism-of-action-of-GLP-1-25.png)
US$ 21.54
